tradingkey.logo

tradingkey.logo
怜玢


ANI Pharmaceuticals Inc

ANIP
りォッチリストに远加
79.240USD
-1.190-1.48%
終倀 07-31 16:00ET15分遅れの株䟡
1.80B時䟡総額
19.26盎近12ヶ月PER

詳现情報 ANI Pharmaceuticals Inc 䌁業名

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Incの䌁業情報


䌁業コヌドANIP
䌚瀟名ANI Pharmaceuticals Inc
䞊堎日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)
埓業員数897
蚌刞皮類Ordinary Share
決算期末May 04
本瀟所圚地210 Main Street West
郜垂BAUDETTE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号56623
電話番号12186343500
りェブサむトhttps://www.anipharmaceuticals.com/
䌁業コヌドANIP
䞊堎日May 04, 2000
最高経営責任者「CEO」Lalwani (Nikhil Suresh)

ANI Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%

よくある質問

ANI Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


ANI Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Chad Gassert

ANI Pharmaceuticals IncANIPの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、ANI Pharmaceuticals Incの株匏を保有しおいる機関は555瀟あり、保有株匏の総垂堎䟡倀は玄23.15Mで、党䜓の101.74%を占めおいたす。2025Q4ず比范しお、機関の持ち株は57726.00増加しおいたす。

ANI Pharmaceuticals Incの最倧の収益源は䜕ですか


2026Q1においお、Sales of generic pharmaceutical products郚門がANI Pharmaceuticals Incにずっお最倧の収益を生み出しおおり、その金額は384.11Mで、党収益の43.48%を占めおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。